ForecastedResearch announcementOpportunity PAR-28-059

Translational Research in Maternal and Pediatric Pharmacology and Therapeutics

National Institutes of Health · Department of Health and Human Services

At a glance

Translational Research in Maternal and Pediatric Pharmacology and Therapeutics is a forecasted federal grant opportunity from the National Institutes of Health (Department of Health and Human Services). The agency's forecast estimates an application due date of July 9, 2027; forecast dates can change. Applicant types listed as eligible include state governments, county governments, city or township governments, special district governments, independent school districts and 10 more. Cost sharing is not required. It is funded under Assistance Listing 93.865 (Child Health and Human Development Extramural Research).

Summary assembled from the official notice's fields. The official notice governs.

Key facts

Aug 20, 2026Forecast posted
Mar 31, 2027 (est.)Full notice expectednext date
Jul 9, 2027 (est.)Application deadline
Apr 1, 2028 (est.)Est. award date

Posted: Aug 20, 2026
Est. close date: Jul 9, 2027
Est. award date: Apr 1, 2028
Award floor: Not specified
Award ceiling: Not specified
Est. total funding: Not specified
Expected awards: Not specified
Cost sharing: Not required
Funding instrument: Grant
Opportunity category: Discretionary
Fiscal year: FY2028

Typical awards for this program (SAM.gov listing for ALN 93.865, not this notice): For research project grants, fiscal year 2024, range is $50,000 to $5,000,000; average is $534,606. Individual research fellowship awards: Basic stipend (first year beyond the doctoral degree) of approximately $45,000. The sponsoring institution will be provided, on application, with an allowance of up to approximately $8,000 per year to help defray the cost of training. No dependency allowances. SBIR: Average Phase I awards are for approximately $225,000 (grant activity R43 - for up to six months); Phase II awards may be made for amounts up to $1,500,000 (grant activity R44 - for up to two years).

Who can apply

State governments
County governments
City or township governments
Special district governments
Independent school districts
Public colleges & universities
Federally recognized tribal governments
Public & Indian housing authorities
Native American tribal organizations
501(c)(3) nonprofits
Nonprofits without 501(c)(3) status
Private colleges & universities
For-profit organizations (not small businesses)
Small businesses
Others (see notice)

Additional information on eligibility (from the notice)

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Can your organization apply?

A quick check against the listed applicant types — other requirements in the notice still apply.

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), as part of its stewardship of Congressionally-mandated activities under the Best Pharmaceuticals for Children Act (BPCA) and implementation of recommendations of the Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC), intends to renew and publish a Notice of Funding Opportunity (NOFO) to solicit applications to promote translational and clinical research in pregnant women, lactating women, infants, children, and adolescents to: (1) advance precision medicine through the development, testing, and implementation of novel tools, models, and other technologies; (2) discover and develop novel therapeutics or enhance the usage of existing drugs for safer and more effective medications; (3) enhance patient-provider communications about drug effectiveness and safety risks; and, (4) optimize the dissemination, implementation, sustainment, and scale-up of evidence-based interventions to these patient populations. The overall goal is to improve safe and effective precision therapeutics during pregnancy, lactation, and across childhood. Applications are not being solicited at this time.

How to apply

0 of 7 done · progress saved in this browser

Read the full announcement (NOFO)Eligibility, evaluation criteria, page limits and required attachments are in the full notice on Grants.gov. Open ↗
Confirm eligibility and fitCheck your organization type above; no cost sharing is required.
Register (or renew) in SAM.gov and get a UEIFree. New registrations can take several weeks; registrations must be renewed every year. Open ↗
Set up Grants.gov accessCreate a Grants.gov account and make sure someone has the Authorized Organization Representative (AOR) role. Open ↗
Watch for the full noticeThe agency estimates posting it around March 31, 2027. Save this grant to track changes.
Prepare narrative, budget and attachmentsFollow the notice's format exactly — page limits and required forms are common reasons applications are rejected.
Submit before July 9, 2027Submit a few days early and keep your Grants.gov confirmation and validation emails.

Assistance Listing

What is an ALN?

93.865Child Health and Human Development Extramural ResearchProgram →

Reported obligations under ALN 93.865

Historical data · not a prediction

FY24

$1.28B

FY25

$1.33B

FY26

$185M est.

Source: SAM.gov Assistance Listing 93.865. Program-wide totals, not awards from this specific opportunity.

Who was funded under ALN 93.865

Historical data · not a prediction

Since October 1, 2023, 6,805 grant awards had funding actions under Child Health and Human Development Extramural Research, with 5,427 sub-awards passed on to other organizations. These are program-wide awards, not awards from this specific notice.

REGENTS OF THE UNIVERSITY OF MICHIGAN$111M
UNIVERSITY OF WASHINGTON$99.9M
THE JOHNS HOPKINS UNIVERSITY$92.1M
REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE$77M
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE$74.4M

Recipients, states, recent awards and sub-awards →Source: USAspending.gov.

Agency contact (as published)

Obstetric and Pediatric Pharmacology and Therapeutics Branch (OPPTB) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Please contact via e-mail

Quick answers

Is “Translational Research in Maternal and Pediatric Pharmacology and Therapeutics” open for applications yet?

Not yet. It is a forecast — an agency's advance notice of an expected opportunity. The agency estimates posting the full notice around March 31, 2027. Forecast details and dates can change.

Who is eligible to apply for “Translational Research in Maternal and Pediatric Pharmacology and Therapeutics”?

The official notice names these applicant types as eligible: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public colleges & universities, Federally recognized tribal governments, Public & Indian housing authorities, Native American tribal organizations, 501(c)(3) nonprofits, Nonprofits without 501(c)(3) status, Private colleges & universities and 3 more. Additional restrictions may apply; review the full notice.

How do I apply for “Translational Research in Maternal and Pediatric Pharmacology and Therapeutics”?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity PAR-28-059), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.

ForecastedResearchALN 93.865